News

Avoidance of cardiovascular issues and effects, as well as improved effort to gain control of narcolepsy symptoms, were among the reasons for switching to lower sodium oxybate.

The postdoctoral researcher at the Johns Hopkins Multiple Sclerosis Center shared his perspective on the use of spinal cord atrophy in clinical practice to measure disease progression in MS and how it might become more accessible. [WATCH TIME: 4 minutes]

After a previous analysis showed that natalizumab dosing every 6 weeks can decrease the risk of progressive multifocal leukoencephalopathy, new data showed no differences in patient-reported outcomes vs treatment every 4 weeks.

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Riley Bove, MD; Blake E. Dewey, PhD; Bruce Cree, MD, PhD, MAS; John DeLuca, PhD; Shuvro Roy, MD; and Tanuja Chitnis, MD. [LISTEN TIME: 26 minutes]

The online tool was evaluated in a cohort of 501 patients and healthcare providers, showing positive trends in 9 of 11 outcomes assessed. Notably, disease-modifying therapy start, adherence, and long-term mental health were all improved in the intervention group.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 3, 2022.

Clinician-perceived cognitive deficits of patients with multiple sclerosis were significantly predicted by multiple factors, including cognitive scores, depression, and physical disability, but notably not fatigue.

The agency pushed the PDUFA date back citing new data analyses that constitute a significant amendment to the NDA.

The 1st annual awards ceremony was held during the CMSC Annual Meeting in National Harbor, Maryland.

Individuals with progressive MS demonstrated stable scores on Expanded Disability Status Scale, with no 12-week confirmed disability progression detected.

The associate professor of neurology at UCSF Weill Institute for Neurosciences discussed the findings of a social media listening study that suggested women with multiple sclerosis used social media platforms to discuss treatment during and around pregnancy. [WATCH TIME: 4 minutes]

The form, which is freely available through the Epic and Cerner EHR platforms, was developed to streamline and standardize patient data collection to allow clinicians more time with patients and more consistent information.

The health research assistant at the Shepherd Center discussed the need to improve access to interventions that improve the overall happiness of individuals with multiple sclerosis. [WATCH TIME: 4 minutes]

Episode 23 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the VHA and Albany Medical College; and Robert Holloway, MD, MPH, of University of Rochester School of Medicine and Dentistry. [WATCH TIME: 6 minutes]

A large number of patients with MS were clustered in an area that may have had high exposure levels of aluminum, which the study investigators noted warrants future research.

The professor of neurology at the University of Saskatchewan discussed the need to improve therapeutics aimed at improving neurodegeneration in patients with multiple sclerosis. [WATCH TIME: 3 minutes]

At the end of the open-label extension period, 77.5% of patients reported treatment-emergent adverse events and 27.7% had a treatment-related TEAE.

Investigators utilized a social media listening tool to evaluate and scale mentions of disease-modifying therapy use by women with multiple sclerosis, with the majority of concerns focused on safety and treatment reinitiation in the postpartum period.

Although there were no differences between herpes simplex virus types 1 and 2, patients with MS did show increased levels of EBV capsid antigen and EBNA compared with controls.

Both ozanimod doses were associated with greater median reductions in plasma neurofilament light and mean improvements in SDMT score change than interferon beta-1a at month 12 of treatment.

The professor of neurology at the University of Saskatchewan discussed his presentation at the 2022 CMSC Annual Meeting on using ribonucleoprotein A1 antibodies to drive neurodegeneration in multiple sclerosis. [WATCH TIME: 4 minutes]

The founder and chief medical officer of Omniscient Neurotechnology discussed how the use of machine learning and big data will be critical in revolutionizing our understanding of the brain and mental illnesses.

The FDA is set to complete its review of FT218 by June 17, 2023, and Avadel has indicated its expectation that the investigational treatment for excessive daytime sleepiness and cataplexy in adults with narcolepsy will be approved.

Data from the RAINBOWFISH study and a large-scale extension, FIREFISH, were the basis for risdiplam’s expanded indication, which now includes babies with SMA under 2 months old.

More than 60% of adolescents felt that it was more important to measure decreases in the frequency and intensity of headaches in terms of severe headaches/spikes rather than total headache days.

Stephen Krieger, MD, of the Icahn School of Medicine and Corinne Goldsmith Dickinson Center for MS at Mount Sinai, shared his perspectives on the trends in multiple sclerosis and the need to holistically treat patients to maximize brain reserve.

Emily Harrington, MD, PhD, physician-scientist at The Ohio State University Wexner Medical Center, provided thoughts on the importance of World MS Day and the issues that plague the MS community.

The professor of neurology at MedStar Georgetown University Hospital shared his perspective on the trends in thinking about the treatment of MS and how an improved understanding of underlying processes has led to a shift in the field. [WATCH TIME: 5 minutes]

Here's what is coming soon to NeurologyLive®.

Investigators identified a duration-response pattern that was also present within the strata of high vs low-medium intensity statin therapy in a cohort of more than 16,000 individuals.